Vimarsana
Biggest News Aggregation in the World

Page 16 - Vida Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vida Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vida Ventures Today - Breaking & Trending Today

Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders - Vimarsana News

Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders

Share: Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito's third international investment in H2 2020, with deep and rapidly accelerating pipeline Therachon's Founder, Elvire Gouze, launches latest new gene therapy company in her field of excellence €20 million Series A financing, sees Jeito co-investing again with Vida Ventures Paris, France, 14 December 2020 – Jeito Capital ("Jeito"), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a €20 million Ser...

Gene therapy player InnoSkel debuts with €20M for rare skeletal diseases - Vimarsana News

Gene therapy player InnoSkel debuts with €20M for rare skeletal diseases

(iStock/Getty Images Plus/Stork)(iStock / Getty Images Plus / Stork) Elvire Gouze Ph.D., a serial entrepreneur and expert in skeletal disorders, has formed another company—InnoSkel—after agreeing to sell her first venture Therachon to Pfizer for $340 million upfront last year. Like Therachon, InnoSkel is focusing on diseases that result in dwarfism, but using a different approach. Therachon’s lead drug TA-46 was a soluble FGFR3 receptor designed to interrupt a molecule pathway linked to dwarfism, but InnoSkel will focus on gene therapies that will target underlying defects as a...

Locanabio Finds $100M For Gene Therapy - Vimarsana News

Locanabio Finds $100M For Gene Therapy

socaltech.com San Diego-based Locanabio, a biotech startup developing gene therapy to treat neurodegenerative, neuromuscular, and retinal diseases, has raised $100M in a Series B funding, the company said this morning. The funding was led by Vida Ventures, and also included RA Capital Management, Invus, Acuta Capital Partners and an investment fund associated with SVB Leerink, plus prior investors ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures and GV. Locanabio is led by CEO Jim Burns. The company said the financing will advance Locanabio's portfolio of RNA-targeted gene t...